Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
The Rust reimplementation of GNU Coreutils is faster, runs in the browser, and secures system calls better. What version 0.8 ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Let's be honest, we're all drama queens sometimes. Whether you're texting your bestie you're “literally dying” over the latest celebrity gossip or declaring on social media that Monday mornings are ...
Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Yarilet Perez is an experienced multimedia journalist and fact-checker with a Master of ...
Bondi's tenure was marked by the Epstein files and efforts related to punishing Trump's perceived enemies by Nik Popli by Eric Cortellessa Will Oliver—EPA/Bloomberg ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results